AdvisorShares Investments’s Idexx Laboratories IDXX Stock Holding History

AdvisorShares Investments’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,194	Closed	-$895K	–	311
2022 Q4	$895K	Buy	+2,194	New	+$852K	0.25%	70
2020 Q3	–	Sell	-3,036	Closed	-$1M	–	144
2020 Q2	$1M	Buy	+3,036	New	+$879K	0.43%	42

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AdvisorShares Investments's IDXX Position: Q1 2023 in Review

AdvisorShares Investments sold out of Idexx Laboratories (IDXX) in Q1 2023, closing a stake of 2,194 shares — an estimated $895K sold.

AdvisorShares Investments first reported a position in IDXX in Q2 2020 and held it in 2 quarters. The position peaked at $1M in Q2 2020. 1,055 funds tracked by Wall St. Rank hold IDXX as of Q1 2023.

AdvisorShares Investments reported no remaining Idexx Laboratories position as of Q1 2023 after selling out during the quarter.
AdvisorShares Investments sold 2,194 Idexx Laboratories shares in Q1 2023, an estimated $895K.
AdvisorShares Investments first reported a position in Idexx Laboratories in Q2 2020 and held it in 2 quarters.
AdvisorShares Investments's Idexx Laboratories position peaked at $1M in Q2 2020.
1,055 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2023.

Based on AdvisorShares Investments's 13F filing for Q1 2023, filed 9 May 2023.